Moreover, bortezomib-resistant mantle cell lymphoma cells were also found to exhibit elevated CD36 expression levels, increased FA uptake, and could similarly be re-sensitized to bortezomib with a function-blocking antibody of CD36 [68]. This evidence concerns the gene CD36 and mantle cell lymphoma.